The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seattle Genetics
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech
Se Hoon Park
Honoraria - Merck Sharp & Dohme; Sanofi/Aventis
Consulting or Advisory Role - Janssen Oncology; Lilly
Research Funding - Kura Oncology; Ono Pharmaceutical
Eric Voog
No Relationships to Disclose
Claudia Caserta
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Merck; Novartis; Pfizer
B.P. Valderrama
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; EUSA Pharma; Ipsen; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Pfizer; Roche
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca
Haralabos Kalofonos
No Relationships to Disclose
Sinisa Radulovic
No Relationships to Disclose
Wim Demey
No Relationships to Disclose
Anders Ullén
No Relationships to Disclose
Yohann Loriot
Honoraria - Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seattle Genetics
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seattle Genetics
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
Norihiko Tsuchiya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Evgeny Kopyltsov
No Relationships to Disclose
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Incyte; Medscape; Merck; MSD; Pfizer; Roche; Roche/Genentech; UroToday
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
Jeanny B. Aragon-Ching
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Algeta/Bayer; AstraZeneca; AstraZeneca/MedImmune; Dendreon; EMD Serono; Janssen Biotech; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho
Travel, Accommodations, Expenses - Algeta/Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seattle Genetics; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seattle Genetics (Inst)
Expert Testimony - Celgene; sanofi
Alessandra di Pietro
No Relationships to Disclose
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seattle Genetics
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)